Alpha-emitting complexes
US10682430B2 · kind B2 · utility
1Cited by
15References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 21, 2017 |
| Grant date | Jun 16, 2020 |
| Priority date | — |
| Expiry date | Jun 21, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.